We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides

By LabMedica International staff writers
Posted on 23 Apr 2026

Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. More...

Nearly 20 million new cases are diagnosed each year, and traditional artificial intelligence (AI) tools require massive datasets and repeated retraining for each tumor type. These hurdles slow deployment, particularly across diverse clinical settings. Researchers now introduce a plug-and-play pathology system that classifies multiple cancers from only a few annotated slides.

At The Hong Kong University of Science and Technology (HKUST), investigators developed PRET (Pan-cancer Recognition without Example Training), a pathology analysis system designed to recognize multiple tumor types from minimal samples without additional training. Positioned as a plug-and-play tool for digital pathology, PRET targets routine diagnostic tasks that can burden laboratory workflows.

The system applies “in-context learning,” a strategy adapted from natural language processing, to whole-slide image analysis. During inference, PRET adapts to new cancer types and tasks by referencing just one to eight annotated tumor slides, rather than relying on task-specific fine-tuning. The approach is described as supporting cancer screening, tumor subtyping, tumor segmentation, and lymph node metastasis detection.

Validation drew on 23 international benchmark datasets from institutions in the Chinese Mainland, the United States, and the Netherlands, encompassing 18 cancer types and multiple diagnostic tasks. PRET demonstrated stable, robust generalizability across different populations and regions with varying medical resources. The evaluation addressed clinically relevant endpoints across settings.

Across these datasets, the system outperformed existing methods in 20 tasks. Its area under the curve (AUC), a measure of diagnostic accuracy, exceeded 97% in 15 tasks; results included an AUC of 100% in colorectal cancer screening and 99.54% in esophageal squamous cell carcinoma tumor segmentation. For lymph node metastasis detection, PRET achieved an AUC of approximately 98.71% using only eight slide samples, surpassing the average performance of 11 pathologists, whose AUC averaged approximately 81%.

The study is published in Nature Cancer. Collaborating institutions included Guangdong Provincial People’s Hospital and Harvard Medical School. The team plans to further enhance performance and extend applications to genetic mutation prediction and patient prognosis assessment.

“The core value of the PRET system lies in breaking down the traditional barriers of ‘massive data and repetitive training,’ enabling AI-powered pathology systems to be applied in real clinical settings at lower cost and with greater flexibility. This not only helps alleviate the workload pressure faced by pathologists, but also has the potential to improve access to cancer diagnosis in underserved regions,” said Prof. Li Xiaomeng, Assistant Professor of the Department of Electronic and Computer Engineering and Associate Director of the Center for Medical Imaging and Analysis, The Hong Kong University of Science and Technology.

“Through this ‘plug-and-play’ system, we hope that advanced and precise AI-powered diagnostic services can transcend geographical and resource constraints, thereby promoting global health care equity,” said Prof. Li Xiaomeng.

Related Links
HKUST


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Electrolyte Analyzer
BKE-B
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.